MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
26.19
-0.15
-0.57%
After Hours: 26.12 -0.07 -0.26% 19:34 02/06 EST
OPEN
26.97
PREV CLOSE
26.34
HIGH
27.78
LOW
26.08
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
28.29
52 WEEK LOW
2.760
MARKET CAP
3.20B
P/E (TTM)
-6.7947
1D
5D
1M
3M
1Y
5Y
1D
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook
Simply Wall St · 2d ago
Alumis to Participate in Upcoming February Investor Conferences
Barchart · 3d ago
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
Benzinga · 6d ago
Alumis rises 7.8%
TipRanks · 6d ago
Weekly Report: what happened at ALMS last week (0126-0130)?
Weekly Report · 6d ago
Assessing Alumis (ALMS) Valuation After Successful Phase III Results For Envudeucitinib
Simply Wall St · 02/01 10:28
Did Envudeucitinib’s Phase III Win Just Shift Alumis' (ALMS) Investment Narrative?
Simply Wall St · 01/31 05:36
Weekly Report: what happened at ALMS last week (0119-0123)?
Weekly Report · 01/26 09:20
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.